SMO and rheumatoid arthritis: Combining with our recent report that Shh signaling is aberrantly activated in RA patients and inhibition of the key component of Shh signaling, Smo, decreases proliferation of RA-FLSs, we propose that Smo could be a potential target for the FLSs-directed therapies for RA.